US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects with Social Anxiety Disorder, with an Open-Label Extension (PALISADE-3)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fasedienol (Primary)
Indications Social phobia
Focus Registrational; Therapeutic Use
Acronyms PALISADE-3
Sponsors VistaGen Therapeutics

Most Recent Events

14 Feb 2025 According to Vistagen media release, top-line results are expected later this year.
07 Nov 2024 According to Vistagen media release, company remain on track to produce top-line results in 2025 of this PALISADE-3 trial.
11 Jun 2024 According to Vistagen media release, this trial if successful, has the potential to complement PALISADE-2 in support of a fasedienol U.S. New Drug Application submission.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight